IUGNF (Imugene) Accounts Payable: $6.71 Mil (As of Dec. 2025)


IUGNF Imugene Ltd IUGNF
30 GF Score
Price $0.08
! 4 Warning Signs
View Full Analysis

What is Imugene Accounts Payable?

Imugene IUGNF -8.05% 30 Accounts Payable is $6.71 Mil as of Dec. 2025. GuruFocus rates IUGNF with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Imugene's Accounts Payable for the quarter that ended in Dec. 2025 was $6.71 Mil.

Imugene's quarterly Accounts Payable declined from Dec. 2024 ($8.93 Mil) to Jun. 2025 ($4.45 Mil) but then increased from Jun. 2025 ($4.45 Mil) to Dec. 2025 ($6.71 Mil).

Imugene's annual Accounts Payable increased from Jun. 2023 ($1.57 Mil) to Jun. 2024 ($3.96 Mil) and increased from Jun. 2024 ($3.96 Mil) to Jun. 2025 ($4.45 Mil).

Imugene Accounts Payable Historical Data

* Premium members only.

The historical data trend for Imugene's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Accounts Payable Chart

Imugene Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 3.17 1.57 3.96 4.45

Imugene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.19 3.96 8.93 4.45 6.71
IUGNF
30GF Score
Imugene Ltd IUGNF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imugene Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $6.71 Mil mean?
Imugene (IUGNF) has a Accounts Payable of $6.71 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Imugene and its competitors.
Is Imugene's Accounts Payable too high?
Imugene's current Accounts Payable is $6.71 Mil. Overall, Imugene has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Imugene's Accounts Payable compare to VRTX and REGN?
Imugene's Accounts Payable of $6.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Imugene and its competitors. Imugene's current Accounts Payable is $6.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imugene stock overvalued right now?
Imugene (IUGNF) has a current Accounts Payable of $6.71 Mil. The current Accounts Payable is $6.71 Mil. Imugene's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Imugene (IUGNF), the current Accounts Payable is $6.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imugene Business Description

Other Exchanges ILA:GermanyIMU:Australia
Address 4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
30GF Score

Get the complete analysis for IUGNF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price